Neoplasm, Residual: all 272 studies
Page 1 of 3. Open to participants first (124), then studies with results posted, then the rest; newest registration first within each.
- Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple MyelomaRecruitingNCT07891923Phase 2
- MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLCNot yet recruitingNCT07885709Phase 2
- MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLCNot yet recruitingNCT07873086Not applicable
- BLinatumomab and iNKT in Relapsed B-Cell ALLNot yet recruitingNCT07869368Phase 1
- SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete ResponseNot yet recruitingNCT07856303Phase 2
- ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon CancerRecruitingNCT07841236Phase 2
- CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid LeukemiaNot yet recruitingNCT07841002Phase 1
- CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple MyelomaNot yet recruitingNCT07830485Phase 2
- A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and ChemotherapyNot yet recruitingNCT07823322Phase 2
- Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy FailureEnrolling by invitationNCT07813390Phase 2
- Perioperative Adebrelimab for Locally Advanced Cervical CancerNot yet recruitingNCT07811375Phase 2
- Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial CancerRecruitingNCT07756437
- Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.Not yet recruitingNCT07748689Phase 2
- Methylation Profile Test (Methylscape) in Body Fluids for Multi-Cancer Detection and Monitoring in ColombiaRecruitingNCT07741435
- A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable DiseaseNot yet recruitingNCT07740486Phase 3
- TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)Not yet recruitingNCT07720843Phase 1
- Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC PatientsNot yet recruitingNCT07709585Phase 2
- Monitoring MRD in Multiple Myeloma in Serum by Mass SpectrometryNot yet recruitingNCT07691034
- Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic LeukemiaNot yet recruitingNCT07690891Phase 2
- Blood-Based Minimal Residual Disease in Advanced Epithelial Ovarian Cancer After 1st Line TherapyNot yet recruitingNCT07670962
- Determining Minimal Residual Disease Using ctDNA Deep SequencingRecruitingNCT07660627Not applicable
- Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk Recurrent Renal CarcinomaRecruitingNCT07657325
- ctDNA Monitoring After Pancreatic Cancer Surgery (K-4CARE Lite Study)Not yet recruitingNCT07597252
- A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic TransplantNot yet recruitingNCT07572929Phase 2
- VEN+IDAC vs IDAC in AMLEnrolling by invitationNCT07537257Phase 2/3
- Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)RecruitingNCT07524114
- MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell LymphomaNot yet recruitingNCT07517705Phase 2
- Proof of Concept for Real-time Multicentric Monitoring of MRD by PET and ctDNA in Aggressive B-Cell LymphomasNot yet recruitingNCT07514715
- Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete RemissionRecruitingNCT07507318Phase 2
- Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AMLRecruitingNCT07500441
- Study of Cell-free DNA in Children and Adolescents With Acute Lymphoblastic LeukemiaRecruitingNCT07483476
- TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World CohortNot yet recruitingNCT07454486
- Treatment for Ph-negative ALL for Adults up to 65 YearsNot yet recruitingNCT07443592Not applicable
- CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCTRecruitingNCT07441291Phase 3
- Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled TrialNot yet recruitingNCT07413146Not applicable
- Motixafortide for MRD Sensitization in AMLRecruitingNCT07392970Phase 2
- Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical CancerNot yet recruitingNCT07382505
- European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin LymphomaRecruitingNCT07356882
- Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCCNot yet recruitingNCT07350824Not applicable
- BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia PatientsNot yet recruitingNCT07301138Phase 2
- To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)RecruitingNCT07291921
- To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCTRecruitingNCT07280494Phase 1
- Automated vs Manual Flow-cytometry Gating for Measurable Residual Disease in Acute Myeloid Leukaemia (DUALFLOW)Not yet recruitingNCT07269067
- Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical StudyNot yet recruitingNCT07264010Phase 2/3
- Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)Not yet recruitingNCT07257380Phase 2
- Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer PatientsNot yet recruitingNCT07247201Phase 1/2
- Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast MalignanciesRecruitingNCT07211178
- cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell CarcinomasRecruitingNCT07178847Not applicable
- A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and VenetoclaxRecruitingNCT07148180Phase 1/2
- MRD-positive AML Clinical StudyRecruitingNCT07131059Not applicable
- Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate CancerNot yet recruitingNCT07112612
- PREDICT-RD: ctDNA Surveillance in TNBC With Residual DiseaseRecruitingNCT07069595Phase 2
- UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AMLRecruitingNCT07059975Early Phase 1
- Risk-adapted Therapeutic Strategy in +1q NDMMNot yet recruitingNCT07045168
- Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast CancerRecruitingNCT07025785Not applicable
- Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNCT07003737Not applicable
- Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)RecruitingNCT06993675Phase 2
- ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)RecruitingNCT06951646Phase 2
- Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic CancerNot yet recruitingNCT06941987
- Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung CancerRecruitingNCT06930807Not applicable
- Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALLRecruitingNCT06886074Phase 2
- Infusion of Alloreactive nk Cells for Mrd-positive Aml PatientsRecruitingNCT06885476Not applicable
- ctDNA in Cutaneous Squamous Cell CarcinomaRecruitingNCT06875609
- A Prospective Study Investigating the Relationship Between Minimal Residual Disease Detection, Monitoring Frequency, and Prognosis in Non-small Cell Lung Cancer Patients Eligible for Curative Treatment.Not yet recruitingNCT06854939
- A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHPRecruitingNCT06828991Phase 2
- NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALLNot yet recruitingNCT06763302Not applicable
- Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and NeckRecruitingNCT06744296
- Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLCNot yet recruitingNCT06709274Not applicable
- ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCLRecruitingNCT06693830Not applicable
- Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid LeukemiaNot yet recruitingNCT06652685Phase 2
- Measuring the Density of Iodine in Lipiodol Depositions: Detecting an Invisible Residual Tumor After Conventional Transarterial Chemoembolization for Hepatocellular CarcinomaNot yet recruitingNCT06602986Not applicable
- Exploratory Research on Constructing a Computational Biological Model Based on NGS for MRD After Breast Cancer SurgeryRecruitingNCT06595966
- VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDSRecruitingNCT06536959Phase 2
- Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung CancerRecruitingNCT06514118
- Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLRecruitingNCT06500273Phase 2
- Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or NotRecruitingNCT06463717
- Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease DetectionRecruitingNCT06409702Phase 4
- Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)Not yet recruitingNCT06323148Phase 3
- Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple MyelomaRecruitingNCT06302699
- French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)RecruitingNCT06287814
- French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)RecruitingNCT06287749
- French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)RecruitingNCT06287723
- Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual DiseaseRecruitingNCT06253650Phase 2
- CtDNA Based MRD Testing for NAC Monitoring in TNBCRecruitingNCT06230185
- Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain ReactionRecruitingNCT06211166
- Assessment of Early Pancreatic Cancer Prognosis by Minimal Residual Disease Using Multi-omics ApproachNot yet recruitingNCT06151691
- A Study of Tetrathiomolybdate (TM) Plus CapecitabineRecruitingNCT06134375Phase 1/2
- Relugolix + Enzalutamide Study in High-Risk Prostate CancerRecruitingNCT06130995Phase 1
- GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal CancerRecruitingNCT06111105
- A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial TreatmentRecruitingNCT06109233
- GUIDING MULTI-MODAL THERAPIES AGAINST MINIMAL RESIDUAL DISEASE BY LIQUID BIOPSIESEnrolling by invitationNCT06102889
- Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and VenetoclaxNot yet recruitingNCT06090786Not applicable
- A Study of Chidamide With AZA in MRD Positive AML After TransplantRecruitingNCT06066905Not applicable
- Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD TechnologyRecruitingNCT05969938
- Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in BrazilRecruitingNCT05959720
- Evaluation of 3D Ultrasound in Brain Tumor SurgeryRecruitingNCT05956977Not applicable
- Minimally Residual of Esophageal Cancer 001RecruitingNCT05952661
- Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana LinfomiRecruitingNCT05929222Phase 3
- Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AMLRecruitingNCT05904106Phase 2
- Efficacy Evaluation and Recurrence Monitoring of Therapy for Esophageal Squamous Cell Carcinoma Based on ctDNA-MRD.Not yet recruitingNCT05900583